Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the effects of BDP HFA Nasal Aerosol on HPA-axis function.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Teva Branded Pharmaceutical Products, R&D Inc.
• Treatments: Beclomethasone; Prednisone

Criteria

Inclusion Criteria:

• Informed Consent

• Male or female subjects 12-45 years of age

• Documented history of perennial allergic rhinitis

• General good health

• Other criteria apply

Exclusion Criteria:

• History of physical findings of nasal pathology (within 60 days prior to Screening Visit 1)

• Participation in any investigational drug study 30 days preceding Screening Visit 1

• History of respiratory infection/disorder with 14 days preceding Screening Visit 1

• Use of any prohibited concomitant medications